Bio-Techne (TECH) Total Non-Current Liabilities (2014 - 2026)
Bio-Techne's (TECH) quarterly Total Non-Current Liabilities came in at $2.5 billion in Q1 2026, down 3.79% year-on-year from $2.6 billion in Q1 2025, and up 1.17% quarter-over-quarter from $2.5 billion in Q4 2025.
Bio-Techne (TECH) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Bio-Techne's Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $2.5 billion for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 3.79% year-over-year to $2.5 billion in Q1 2026; TTM through Mar 2026 was $2.5 billion, a 3.79% decrease from a year earlier, with the FY2025 full-year figure at $2.5 billion, down 5.94% from the prior year.
- Total Non-Current Liabilities rose to $2.5 billion in Q1 2026 per TECH's latest filing, from $2.5 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.7 billion in Q3 2023 and bottomed at $2.3 billion in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $2.6 billion (2023), against an average of $2.6 billion.
- Across the five-year window, Total Non-Current Liabilities advanced 17.39% in 2023 and decreased 7.87% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $2.4 billion in 2022, then climbed by 15.36% to $2.7 billion in 2023, then declined by 2.0% to $2.7 billion in 2024, then slipped by 6.0% to $2.5 billion in 2025, then advanced by 1.17% to $2.5 billion in 2026.
- Per Business Quant, the three latest TECH Total Non-Current Liabilities figures stand at $2.5 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Bio-Techne | 11.23 Bn | 11.02 Bn | 208.29 Mn | 2.53 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.53 Bn |
| Dec 31, 2025 | 2.50 Bn |
| Sep 30, 2025 | 2.50 Bn |
| Jun 30, 2025 | 2.53 Bn |
| Mar 31, 2025 | 2.63 Bn |
| Dec 31, 2024 | 2.66 Bn |
| Sep 30, 2024 | 2.72 Bn |
| Jun 30, 2024 | 2.69 Bn |
| Mar 31, 2024 | 2.71 Bn |
| Dec 31, 2023 | 2.71 Bn |
| Sep 30, 2023 | 2.75 Bn |
| Jun 30, 2023 | 2.63 Bn |
| Mar 31, 2023 | 2.59 Bn |
| Dec 31, 2022 | 2.35 Bn |
| Sep 30, 2022 | 2.34 Bn |
| Jun 30, 2022 | 2.29 Bn |
| Mar 31, 2022 | 2.29 Bn |
| Dec 31, 2021 | 2.30 Bn |
| Sep 30, 2021 | 2.25 Bn |
| Jun 30, 2021 | 2.24 Bn |